The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Eisai

Status and phase

Completed

Phase 3

Conditions

Dementia With Parkinson's Disease

Treatments

Drug: ARICEPT

Study type

Interventional

Funder types

Industry

Identifiers

NCT00165815

E2020-E044-316

Details and patient eligibility

About

A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Patients with an established diagnosis of PD and dementia, who fulfill all of the inclusion criteria and none of the exclusion criteria listed below, will be eligible for enrolment into this study.

Best efforts must be made on clinical grounds to exclude patients with DLB and AD. The key inclusion criteria in this respect is the onset of dementia documented to have occurred at least 1 year after the diagnosis of PD.